Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA

 
• By Derrick Gingery, Sarah Karlin-Smith, and Nielsen Hobbs

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.

Pink Sheet podcast
Will FDA collaboration with PMDA increase once the Japanese regulator opens an office in Washington D.C.? • Source: Citeline/Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews